We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vermillion Announces Issuance of U.S. Patent Covering the Discovery of Novel Forms of Brain Natriuretic Peptide
News

Vermillion Announces Issuance of U.S. Patent Covering the Discovery of Novel Forms of Brain Natriuretic Peptide

Vermillion Announces Issuance of U.S. Patent Covering the Discovery of Novel Forms of Brain Natriuretic Peptide
News

Vermillion Announces Issuance of U.S. Patent Covering the Discovery of Novel Forms of Brain Natriuretic Peptide

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vermillion Announces Issuance of U.S. Patent Covering the Discovery of Novel Forms of Brain Natriuretic Peptide"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vermillion, Inc. has announced that the U.S. Patent Office (USPTO) has issued the Company Patent No. 7,341,838 for the discovery of novel forms of brain natriuretic peptide (BNP), which could potentially improve upon the current standard of care in diagnosing and treating cardiovascular disease, Vermilliom says.

According to Company, the discovery could ultimately lead to the development of a next-generation assay that might provide physicians with additional, valuable information to stratify patients at risk for cardiovascular disease, including stroke and congestive heart failure.

"The issuance of this patent validates the strength of our approach in the development of innovative molecular diagnostics," said Eric T. Fung, M.D., Ph.D., Chief Scientific Officer of Vermillion. "We hypothesize that measuring these novel forms of BNP will have prognostic value. We look forward to continuing to build our solid pipeline of potential biomarkers to aid in the diagnosis of serious, debilitating conditions."

BNP is secreted by the heart and indicates how well the muscle is working. Normally, only a low amount of BNP is found in the blood. However, if the heart has to work harder than usual over an extended period of time the heart releases more BNP. Elevated levels of BNP can signify congestive heart failure.

The patent also covers the measurement of these new modifications of BNP by a variety of methods, including SELDI (surface enhanced laser desorption/ionization) mass spectrometry -- which was used to discover these specific forms -- and other immunoassay approaches.

Advertisement